14040 Danielson Street
250 articles with ResMed Inc.
ResMed announced it plans to release financial and operational results for the first quarter of fiscal year 2020 on Thursday, October 24, 2019, after the New York Stock Exchange closes.
Bank of America Merrill Lynch Global Healthcare Conference on Thursday, September 19, 2019, beginning at approximately 11:25 a.m. (British Summer Time) at the Bank of America Merrill Lynch Financial Centre in London.
17th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019, beginning at approximately 2:50 p.m. (Eastern Time) at the Grand Hyatt New York in New York City.
ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected health company, today announced results for its quarter ended June 30, 2019.
ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2019 on Thursday, July 25, 2019, after the New York Stock Exchange closes.
Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.
170 million people in North and South America have sleep apnea, ResMed study finds Researchers urge more screenings and cloud-connected treatment devices to curb growing health crisis
ResMed (NYSE: RMD, ASX: RMD) today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m. (Pacific Time) at the Terranea Resort in Rancho Palos Verdes, Calif.
ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m. (Central Time) at the Loews Chicago Hotel in Chicago.
Study presented at ATS International Conference examined more than 4 million PAP users in U.S., Brazil, Mexico
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought
ResMed revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference.
De Witte’s 30+ years of global healthcare and technology experience will bolster ResMed’s board capabilities
Year-over-year revenue grows 12%, gross margin improves 100 basis points, operating profit up 15%
Now offers “tube-up” design options for nasal and nasal pillows mask wearers, providing even more flexibility and choice to help users sleep better in any position
ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes.
Brand-agnostic solution helps HMEs provide timely PAP replacement supplies to sleep apnea patients, increases long-term adherence and improves satisfaction
ResMed announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software.
ResMed Acquires HB Healthcare to Help Millions of Koreans Living with Sleep Apnea, Other Respiratory Conditions
ResMed, a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, announced that is has completed the acquisition of HB Healthcare to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions.
Settlement will end infringement cases worldwide
- AirFit N30i adds a top-of-head mask-to-tube connection to ResMed’s expanding CPAP mask portfolio, helps the wearer move and sleep in any position - New “cradle” cushion sits under the nose, designed to reduce facial markings and irritation